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Dihydrofolate reductase (DHFR) is a critical enzyme in folate metabolism and an important target of antineoplastic, antimicrobial, and
antiinflammatory drugs. We describe three individuals from two families with a recessive inborn error of metabolism, characterized by
megaloblastic anemia and/or pancytopenia, severe cerebral folate deficiency, and cerebral tetrahydrobiopterin deficiency due to a germ-
line missense mutation in DHFR, resulting in profound enzyme deficiency. We show that cerebral folate levels, anemia, and pancyto-
penia of DHFR deficiency can be corrected by treatment with folinic acid. The characterization of this disorder provides evidence for
the link between DHFR and metabolism of cerebral tetrahydrobiopterin, which is required for the formation of dopamine, serotonin,
and norepinephrine and for the hydroxylation of aromatic amino acids. Moreover, this relationship provides insight into the role of
folates in neurological conditions, including depression, Alzheimer disease, and Parkinson disease.Folates are critical cofactors for single-carbon metabolism
in biological processes, including DNA synthesis, regula-
tion of gene expression, and synthesis of amino acids,
neurotransmitters, and myelin.1 Systemic folate defi-
ciency, most frequently due to dietary insufficiency, mani-
fests as biochemical, hematological and neurological
disturbance. Six inherited disorders of folate transport
and metabolism have been described (Table S1 available
online). Of particular note, mutations in FOLR1 (MIM
136430), encoding folate receptor alpha, cause a brain
specific folate-transport defect that manifests between 2
and 3 years of age and is characterized by irritability,
slow head growth, psychomotor retardation, cerebellar
ataxia, pyramidal tract signs, dyskinesia, and seizures.2
The only consistent biochemical abnormality observed in
children affected with FOLR1 mutations is a low level of
5-methyltetrahydrofolate (5-MTHF) in the cerebrospinal
fluid (CSF) with normal serum and erythrocyte folate
levels. Cerebral folate deficiency (CFD) can also result
from impaired transport of 5-MTHF across the blood-CSF
barrier due to antibodies to folate receptors.3 Here, we
describe the clinical features and molecular mechanism
of an inborn error of folate metabolism characterized by
infantile-onset megaloblastic anemia and/or pancyto-
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child of first-cousin British Pakistani parents (I-1 and I-2),
born at full term after an uneventful pregnancy and with
no neonatal problems. His weight and head circumference
(HC) at birth were 2.83 kg (9th–25th centile) and 33 cm
(2nd–9th centile), respectively. He presented at 4 mo of
age with increasing pallor, poor feeding, and secondary
microcephaly with an HC of 36.8 cm (< 0.4th centile).
Investigations revealed severe anemia (Table 1), and his
blood film showed a dual red cell population with oval
macrocytes and microcytes and hypersegmented neutro-
phils (Figure S1A). Within 2 days, he was pancytopenic.
His bone marrow demonstrated megaloblastic erythropoe-
sis (Figure 1B). Serum folate, vitamin B12, and ferritin levels
were normal. Aworking diagnosis of transcobalamin II defi-
ciency (MIM 275350) was made, and hydroxocobalamin
was started. After 1 week, he started having generalized
tonic-clonic and right-sided focal seizures that were refrac-
tory to phenytoin, benzodiazepines, and pyridoxine. His
hematological profile remained unresponsive to hydroxo-
cobalamin. Partial seizure control was achieved with
phenobarbitone and levetiracetam. His brain MRI showed
severe cerebellar and cerebral atrophy (Figures 1C, 1D,
and 1E). CSF neurotransmitters were analyzed by high-
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Figure 1. Pedigree of the Family, Bone Marrow
Morphology, and Brain MRI of the Proband
(A) Pedigree of family of the proband (II:6). DNA
from individuals II:2, II:5, and II:6 was used for
the autozygosity mapping.
(B) Proband’s pretreatment bone marrow aspirate
with modified Wright’s stain at 5003 magnifica-
tion demonstrating early and late megaloblasts
(marked by arrows), consistent with megalo-
blastic erythropoesis. Giant metamyelocytes
and excess siderocytes were seen, andmegakaryo-
cytes were reduced (not shown here).
(C) T1-weighted midline sagittal section of brain
MRI at 4 months showing cerebellar vermian
hypoplasia with atrophy of cerebellar hemi-
spheres (marked by arrow) and surrounding
enlarged CSF space (marked by *). The corpus cal-
losum is thin, and cerebral atrophy can also be
seen. Additionally, there was a chronic right sided
subdural collection (not shown), possibly due to
atrophic changes within the brain.
(D) TI-weighted coronal section showing severe
cerebellar atrophy with prominence of the folia.
(E) T2-weighted axial section demonstrating
prominence of the sulci and extensive extraaxial
CSF space. The white matter is poorly myelin-
ated. No abnormality of the basal ganglia is seen.
(F) Proband’s posttreatment marrow aspirate,
confirming return to normoblastic erythropoi-
esis.and/or fluorescence detection4 and revealed markedly
decreasedCSF 5-MTHF,with lowCSFBH4 andnormal dihy-
drobiopterin (BH2) levels (Table 1). Metabolic investiga-
tions showed that there was no methylmalonic aciduria
and that plasma homocysteine and phenylalanine levels
were normal. Table S2provides details of all othermetabolic
investigations that were performed.
Oral folinic acid (30 mg daily) was initiated, after which
anemia (Figure 1F and Figure S1B), seizure control, and CSF
5-MTHF level showed rapid and significant improvement,
although the BH4 level dropped further (Table 1). Now, at
the age of 19 months, the patient remains profoundly de-
layed with central hypotonia, poor head control, and
inability to fix and follow. He has two to three short focal
seizures daily, is fed via gastrostomy, and suffers from
frequent lower respiratory tract infections.
An older sibling (II:3) died at 28 weeks of age with
a history of anemia and intractable seizures of undefined
cause. Postmortem examination showed a small brain,The American Journal of Humweighing 480 g (normal 615 g), with
ventricular dilatation and white matter
atrophy of the cerebrum. There was
neuronal loss in the cerebellar folia with
a reduction of both the internal and
external granular cell layers. Neuronal and
vascular calcifications were seen in the basal
ganglia and subcortical white matter,
respectively, with gliosis in the periventric-
ular white matter and possible optic
atrophy. The cause of death was Klebsiellaaerogenes pneumonia. The proband’s two remaining older
siblings (II-2 and II-5) and parents (I-1 and I-2) are healthy.
CFD andmegaloblastic anemia in the presence of normal
serum folate excluded the possibility of defects in anyof the
known folate transporters.2,5 Absence of hyperhomocystei-
nemia indicated that the defect did not involve themethyl-
ation cycle but was most likely to be in the DNA-synthesis
arm of folate metabolism. Ethical approval for the study
was obtained from the University of Manchester (06138)
and NHS ethics committees (06/Q1406/52). Informed
consent was obtained from all participants or their parents.
We undertook autozygosity mapping and genotyped the
proband (II:6) and two unaffected siblings (II:2 and II:5) by
using the Genome-Wide Human SNP Array 6.0 (Affyme-
trix, Santa Clara, CA, USA) as described previously.6 Geno-
type calls were generated with the use of the Birdseed V2
algorithm within the same software, and the results were
analyzed by AutoSNPa.7 Multiple homozygous regions,
equivalent to approximately 180 Mb and unique to thean Genetics 88, 216–225, February 11, 2011 217
Table 1. The Results of Hematological and CSF Investigations of the Proband
Pretreatment After Folinic Acid Treatment
Investigation
(Reference Range) At Presentation
2 Days after
Presentation
After
Transfusion
After 1 Week
of Treatment
After 1 Month
of Treatment
After 4 Months
of Treatment
Age in months 3.5 3.5 4.5 5 6 9.5
Haemoglobin
(10.0–13.0 g/dl)
5.2 Y 3.7 Y 8.2 Y 8.6 Y 10.6 12.7
Red cell count
(3.80–4.90 3 109/l)
1.9 Y 1.31 Y 3.03 Y 3.18 Y 3.91 4.65
Mean corpuscular
volume (73–88 fl)
85 82 81 84 82 86
White cell count
(6.0–17.0 3 109/l)
8.4 2.3 Y 3.6 Y 5.8 Y 9.2 8.0
Neutrophils
(1.00–6.00 3 109/l)
2.7 0.95 Y 1.76 Y 2.47 2.63 2.78
Lymphocytes
(3.30–11.50 3 109/l)
4.2 1.11 Y 1.34 Y 2.25 Y 5.52 4.19
Monocytes
(0.20 1.30 3 109/l)
0.7 0.17 Y 0.24 0.56 0.76 0.92
Eosinophils
(0.05–1.10 3 109/l)
0.6 0.08 NA 0.55 0.31 NA
Basophils
(0.02–0.20 3 109/l)
0.2 0 Y 0 Y 0.01 Y 0.01 Y 0.01 Y
Platelets
(150–560 3 109/l)
240 138 Y 316 423 390 358
CSF 5-MTHF
(72–305 nmol/l)
NA NA 9 Y 98 NA 81
CSF total neopterin
(7–65 nmol/l)
NA NA 36 20 NA NA
CSF tetrahydrobiopterin
(*nmol/l)
NA NA 23 Y
(27–105)
13 Y
(23–55)
NA NA
CSF dihydrobiopterin
(0.4–13.9 nmol/l)
NA NA 8.9 5.3 NA NA
CSF pyridoxal
phosphate
(*nmol/l)
NA NA 52
(44–89)
51
(23 – 87)
NA NA
CSF homovanillic acid
(*nmol/l)
NA NA 288 Y
(324–1098)
298 Y
(362–955)
NA 330
(176–851)
CSF
5-hydroxyindoleacetic
acid (*nmol/l)
NA NA 198 Y
(199–608)
142
(63–503)
NA 165
(68–451)
Reference ranges for investigations marked with * are age dependent and are given with individual measurements. NA, not available; Y, results below normal.affected individual, were identified (Table S3). This
included a 3 Mb region at chromosome 5q14.1 flanked
by rs4521453 and rs10059759, containing DHFR.
Primers for PCR and sequencing were designed with
Primer3 on the basis of NCBI reference sequence
NM_000791.3, covering the coding regions and intron-
exon boundaries of exons 1 to 6 of the DHFR and ensuring
no amplification of the pseudogenes. Primer sequences and
PCR conditions are provided in Table S4. Sequence variants
were named in accordance with HGV nomenclature, and
NM_000791.3 was used as the reference sequence.
DNA sequence analysis of DHFR revealed a homozygous
missense mutation, c.238C>T (p.Leu80Phe), in exon 3218 The American Journal of Human Genetics 88, 216–225, February(Figure 2A). The mutation segregated with the disorder in
the family (Figure 2B) and, importantly, was homozygous
in DNA extracted from a neonatal blood spot available
from the affected deceased sibling (patient 2, II:3). The
mutation was absent in 292 chromosomes from ethnically
matched Pakistani controls (Figure 2C).
Another child (family 2) with CFD, megaloblastic
anemia, and normal serum folate was ascertained. He is
the first child born to first-cousin British Pakistani parents,
delivered at full term with a birth HC of 33.5 cm (25th
centile). He presented at 10 weeks of age with reduced
oral intake, icterus, and hepatomegaly. His hemoglobin
(Hb) level was 6.1 g/dl, with a mean corpuscular volume11, 2011
Figure 2. Results of Sequencing, Expression
Analyses, Immunoblotting
(A) Sequence trace showing missense mutation
c.238C>T in exon 3 of DHFR. This mutation
was homozygous in the proband (II:6) and two
other affected individuals. The mutation was
heterozygous in I:1, I:2, II:2, and II:5 and in an
unaffected sibling of patient 3. A normal
sequence trace from an ethnically matched
control is also shown.
(B) Expression of DHFR in different fetal tissues
(top panel), adult tissues (middle panel), and
selected brain areas (bottom panel). Relative
expression levels are given as the fold change in
comparison to the tissue or area with the lowest
expression level. All fetal tissues are from 20- or
21-week-old embryos after gestation, except for
cochlear RNA, which was isolated from an
8-week-old embryo.
(C) Immunoblot of protein from cellular and
nuclear lysates from lymphoblast cell lines
derived from the proband, his parents, and an
unrelated control. Mouse monoclonal antibody
to human GAPDH (36 kDa) was used to demon-
strate equal protein loading. Polyclonal antibody
to human DHFR (21 kDa) produced in rabbit was
purchased from ProteinTech (Chicago, IL). DHFR was undetectable in the patient’s sample and was reduced in both parents in compar-
ison to the control. Of note, the expression level of DHFR in parents is slightly different even though they carry the same mutation,
which is probably because DHFR is a dynamically expressed protein.of 95 fl.HisHCwas 37 cm (0.4th–2ndcentile).Within 5 days,
he developed leucopenia (5.4 3 109/l) and thrombocyto-
penia (71 3 109/l). A diagnosis of megaloblastic anemia of
unknown cause was made, and folic acid was started. His
anemia resolved and his neurodevelopment was satisfac-
tory. Folic acidwas stopped at 7.5monthsof age, andwithin
6 weeks he presented in status epilepticus. His brain MRI
demonstrated marked hypoplasia of the cerebellar vermis.
At 11 months of age, his CSF 5-MTHF level was extremely
low, at 3 nmol/l. Treatment 5 mg folinic acid twice daily
was begun. Brain MRI, repeated at 23 months, showed
atrophy of the cerebellar hemispheres, patchy high signal
in the subcortical white matter, and delayed myelination.
Currently, at 5 years of age, he is microcephalic (HC <
0.4th centile), with severe developmental delay and cere-
bellar ataxia. DHFR mutation analysis in this child, appar-
ently unrelated to the proband from family 1, revealed
the same homozygous missense change, p.Leu80Phe.
We screened 20 additional patients with CFD of
unknown etiology: 19 without anemia and one with
anemia but with a low serum folate. No variants in the
DHFR coding sequence were identified in these patients.
Human, mouse, chicken, zebrafish, and Drosophila DHFR
protein sequences were aligned by ClustalW and demon-
strated conservation of the leucine residue at position 80
across species to Drosophila (Figure S2).
We assessed the expression profile of DHFR in human
tissues by quantitative real-time PCR analysis (qPCR),
using SYBR Green and Taqman (both from Applied Biosys-
tems, Foster City, CA, USA) techniques. Total RNA for
qPCR analyses from different adult human brain areas
was purchased from Stratagene (La Jolla, CA, USA), exceptThe Americafor hippocampus, thalamus, and spinal cord total RNA,
which was ordered from Biochain (Hayward, CA, USA).
RNA was available from a human embryonic brain panel
of forebrain, telencephalon, diencephalon, midbrain,
hindbrain, and optic vesicles (MRC Newcastle Brain Tissue
Resource, Newcastle, UK) from Carnegie stage 16 (week 6)
and stage 21 (week 8) human embryos.6 Total RNA from
different human adult and fetal tissues was purchased
from Stratagene Europe (Amsterdam, The Netherlands),
except for cochlear RNA, isolated from an 8-week-old
embryo with the use of the NucleoSpin RNA II Kit
(Macherey-Nagel, Du¨ren, Germany). Whole-blood RNA
was isolated from the proband, his parents, and three
healthy control individuals with the use of the PAXgene
Blood RNA Kit (QIAGEN, Venlo, The Netherlands).
Whole-blood and cochlear RNA was treated with DNase I
(Invitrogen, Leek, The Netherlands), and the concentra-
tion and purity were determined by optical densitometry.
SYBR Green-based QPCR expression analysis was per-
formed on a 7500 Fast Real-Time PCR System with the
use of Power SYBR Green PCR Master Mix (Applied Biosys-
tems). Primers were designed with the use of the primer3
program, and GUSB and PPIB were used as reference genes
(Table S5). Five micrograms of total RNA was transcribed
into cDNA with the use of the iScript cDNA Synthesis Kit
(Bio-Rad Laboratories, Hercules, CA, USA), and cDNA was
purified with the NucleoSpin Extract II Kit (Macherey-
Nagel, Du¨ren, Germany). QPCR quantifications were per-
formed in duplicate on the equivalent of 12.5 ng total
RNA input. Differences in expression of a gene of interest
between two samples were calculated by the comparative
Ct or 2DDCt method.8n Journal of Human Genetics 88, 216–225, February 11, 2011 219
TaqMan-based QPCR analysis was performed on a
StepOne Plus Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). Predesigned, validated primers and
probe mix for DHFR were purchased from Applied Biosys-
tems. 18S and HPRT1 were used as reference genes. Four
hundred nanograms of RNA was transcribed to cDNA
with the use of the high-capacity RNA-to-cDNA Kit
(Applied Biosystems). qPCR quantifications were per-
formed in three triplicate experiments with water controls.
The results were analyzed by StepOne software (Applied
Biosystems). Differences in expression of a gene of interest
between two samples were calculated by the comparative
2DDCt method.
SYBR Green and Taqman real-time PCR analyses demon-
strated that DHFR is widely expressed in fetal and adult
tissues, including throughout the fetal and adult brains
and whole blood (Figure 2B). Of note, expression was
higher in the adult brain than in the fetal brain. Levels of
DHFR transcripts from lymphocytes from the proband
and his heterozygous parents were not significantly
different from each other (data not shown).
We performed an immunoblot on fibroblasts from
a control line and identified very faint bands, even with
high-protein loading, showing that DHFR is expressed rela-
tively poorly in the fibroblasts (data not shown). Therefore,
we undertook immunoblot analysis of cellular and nuclear
lysates from EBV-immortalized lymphoblastoid cells,
which revealed that DHFR was undetectable in the
proband and was present at lower levels in his parents
compared to controls (Figure 2C).
DHFR activity in EBV-immortalized lymphoblastoid cells
was measured by the formation of tetrahydrofolate from
dihydrofolate. A DHFR activity kit (Sigma-Aldrich, St.
Louis, MO, USA) was used for the assay. Lymphoblastoid
cells were incubated with 300 mM NADPH and 250 mM
DHF for 30 min. Samples were stabilized with 10 mM
mercaptoethanol and frozen immediately. Lysates were
prepared from cells with the use of three freeze-thaw
cycles. After centrifugation, the supernatant was acidified
with 10 mM formic acid, and an internal standard
([13C5]-5-methenyltetrahydrofolate) was added. Proteins
were removed by a molecular weight cut-off filter
(Millipore, molecular weight < 10,000). TetrahydrofolateTable 2. The Results ofMeasurement of DHFR Activity and Folate Vitam
Parents
Assay (Units) Reference range Pat
DHFR activity (nmol THF/hr/mg protein) NA 1.5
MTHF (nmol/l) 95–470 169
NonmethylTHF (nmol/l)
measured as THF þ methylene-THF þ
methenyl-THF þ formyl-THF
0–67 77
Dihydrofolate þ folic acid (nmol/l) 0 31
NA, not available; THF, tetrahydrofolate; [, values above the reference range; Y, va
abnormal.
220 The American Journal of Human Genetics 88, 216–225, Februaryconcentration was determined by liquid chromato-
graphy-tandem mass spectrometry (LC-MS/MS).9
DHFR activity in the proband’s immortalized lympho-
blasts was about 100-fold lower compared to controls, con-
firming the diagnosis of DHFR deficiency (Table 2). We
were unable to determine whether the remaining activity
in the proband’s sample was residual DHFR activity or
background activity due to unexpected processes influ-
encing the signal in LC-MS/MS that we considered as
folates. The obligate heterozygote parents showed an inter-
mediate reduced DHFR activity compared to controls.
The effect of the DHFR mutation on the concentrations
of folate vitamers in erythrocytes in vivo was studied with
the use of a previously described method.9 Methylfolate
and nonmethylfolate metabolites were determined by
LC-MS/MS, which distinguishes 5-MTHF, folic acid (sum
of folic acid and dihydrofolate, which converts to folic
acid during assay), nonmethyltetrahydrofolates, and un-
substituted tetrahydrofolate. This showed an accumula-
tion of folic acid and dihydrofolate in the proband, but
not in his heterozygous parents (Table 2).
To explore the mechanism of loss of enzyme activity,
a homology model of the p.Leu80Phe variant was con-
structed with the MOE molecular modeling program,
version 2009.10 (Chemical Computing Group, Montreal,
Canada). Energy minimizations, homology models, and
protein-geometry analysis were performed with the
compute module with the use of the CHARMm22 force
field and a distance-dependent dielectric (3 ¼ 1) as imple-
mented in MOE.
The wild-type crystallographic structure of humanDHFR
(Protein Data Bank [PDB] coordinates 2W3M) was used for
all calculations. The crystallographic waters along with the
NADPH and folate were removed from the structure.
Hydrogens were added at the normal ionization state of
amino acids at pH 7.0, and atomic partial charges were
fixed to the CHARMm22 atom types. To eliminate
potential steric clashes, the backbone atoms of the
protein were tethered to their initial positions by applica-
tion of a tethering force constant of 1 kcal$mol1, and
the initial structure was minimized with the use of a conju-
gate gradient minimization until a convergence of
0.001 kcal$mol1 was attained (Figure 3B).ers in the Proband on Folinic Acid Therapy and in His Heterozygous
ient Mother Father Control 1 Control 2
YY 59.7 Y 52.9 Y 154.7 149.6
117 43 Y NA NA
[ 9.8 45 NA NA
[[ 0 0 NA NA
lues below the reference range. Double arrows indicate values that are severely
11, 2011
To construct a homology model of the p.Leu80Phe
variant, the wild-type human DHFR template structure
(PDB 2W3M) was modified to include the mutation. After
removal of water and ligands and the addition of hydro-
gens and charges as for the wild-type, ten intermediate
models were constructed and scored with the use of
a generalized Born/volume integral internal fitness func-
tion within the MOE homology modeler.10 The model
with the best internal fitness score was selected and sub-
jected to a conjugate gradient minimization with a teth-
ering force as described above, until a convergence of
0.001 kcal$mol1 was attained. The structures for the
wild-type and the p.Leu80Phe mutant of DHFR revealed
that introduction of a phenylalanine induces a shift in
the position of the critical lysine 55 residue, predicting
a significant steric clash and disrupting cofactor binding
for the p.Leu80Phe mutant relative to wild-type DHFR
(Figure 3C).
Homology modeling holds the inherent disadvantage of
exploring only the local conformational space, thus poten-
tially remaining within a local energy minimum that does
not represent the lowest energy structure. Therefore, we
performed a molecular dynamics simulated annealing,
which allowed the backbone and side-chains to sample
the accessible conformational space much more widely
for comparison of the effects of the variant on the struc-
tural integrity and dynamic behavior of DHFR. All molec-
ular dynamics simulated annealing calculations were
performed with the InsightII package, version 2000.1
(Accelrys, San Diego, CA, USA). The Biopolymer, Analysis,
and Decipher modules were used for analysis of molecular
dynamics simulated annealing trajectories. Simulated
annealing calculations were performed with the Discover
module employing the constant valence force field
(CVFF), and calculations were run on an Origin 2000
Silicon Graphics Fuel Server. For the minimized structures
of wild-type and mutant p.Leu80Phe DHFR, atomic poten-
tials were fixed to the default CVFF atom types. The wild-
type and mutant p.Leu80Phe DHFR were then subjected
to a molecular dynamics simulated annealing protocol
according to the following iterative procedure: The struc-
ture was heated to 1000 K over 5 ps, equilibrated at
1000 K for 3 ps, then cooled down to 300 K in 5 ps, with
the use of an exponential rate constant (timtmp) of
0.7 ps for both the heating and cooling steps. The time
step of the molecular dynamics simulations was set to
1 fs, and a distance-dependent dielectric constant of 1
was applied to the system. During the simulated annealing
protocol, the backbone atoms of the protein were tethered
to their initial positions by applying a force constant of
1200 kcal$mol1$A˚2. This force constant sufficiently
restricts the protein backbone to limit local unfolding of
secondary structural elements while allowing for subtle
backbone movements that permit broad side-chain
conformation exploration. After each simulated annealing
cycle, the resulting cooled structures were subjected to
a final energy minimization step involving 1000 steps ofThe Americasteepest descent followed by conjugate gradient minimiza-
tion until a convergence of 0.01 kcal$mol1$A˚2 was
reached. This cycle was repeated nine times for a total
simulation time of 130 ps, yielding ten minimized struc-
tures for the wild-type DHFR. The protocol was repeated
formutant p.Leu80Phe, resulting in tenminimized confor-
mations for the p.Leu80Phe mutant. This analysis sug-
gested that the p.Leu80Phe mutation could result in
potential destabilization of the protein and/or a disruption
of NADPH binding (Figures 3D and 3E).
DHFR catalyzes the NADPH-dependent reduction of
dihydrofolate to tetrahydrofolate, an essential step in the
synthesis of precursors of DNA, including glycine and
purines, and the conversion of deoxyuridine monophos-
phate to deoxythymidine monophosphate.11 It is also
the only enzyme that reduces folic acid, a synthetic
vitamin not found in nature, to dihydrofolate. DHFR is
a key enzyme in all prokaryotes and eukaryotes, being
present in all dividing cells. Cell lines or animal models
deficient in DHFR are considered not viable without sup-
plemented glycine, purines, and thymidine, indicating
its critical role in cellular function. Variants in DHFR,
including a 19 base pair deletion in intron 1, have been
studied in numerous disorders, including breast cancer,12
neural-tube defects,13 and preterm delivery.14 However,
no molecularly confirmed cases of DHFR deficiency have
been described to date. In 1967, Walters reported a child
with megaloblastic anemia and proposed that he may
have DHFR deficiency (T.R. Walters, 1967, Midwest Society
for Pediatric Research, abstract). Skin fibroblasts from this
child were later demonstrated to have normal enzyme
activity.15 In 1976, Tauro et al. reported two neonates
with congenital deficiency of DHFR.16 However, subse-
quent analysis revealed that the first child had methionine
synthase reductase deficiency (MIM 602568),17 and the
second patient was shown to have transcobalamin II defi-
ciency (MIM 275350).18
The phenotype of the patients we describe with biallelic
mutations in DHFR is distinct from patients with the other
recognized disorders of folate metabolism or transport.
Megaloblastic anemia was the presenting feature in our
patients with DHFR deficiency, which resolved completely
with folic acid or folinic acid replacement. In contrast, CSF
5-MTHF levels normalized and seizures responded better to
folinic acid. The neurodevelopmental improvement was
less marked than that reported in patients with FOLR1
mutations and cerebral folate receptor antibodies.2,3 The
presence of cerebral and cerebellar atrophy also distin-
guishes CFD due to DHFR deficiency from other forms of
CFD. Reduced or delayed myelination in the brain may
also be a feature of the condition, but further identification
of patients is required to confirm this, and studies should
be undertaken to understand the mechanism in the
context of normal homocysteine levels. Of note, none of
our patients had a neural-tube defect. The biochemical
profile of DHFR deficiency is unique, given that serum
folate and homocysteine levels were normal in the affectedn Journal of Human Genetics 88, 216–225, February 11, 2011 221
Figure 3. Results of Protein Modeling
(A) Schematic representation of the wild-type nucleotide and amino acid sequence of DHFR, with alternate codons in blue and black and
the intron 3 sequence in gray italics. The mutation in exon 3 and resultant amino acid substitution are given in red.
(B) Normal orientation of Leu80 in the loop region of the crystal structure of wild-type DHFR (PDB coordinates: 2W3M). Leu80 is near
the binding site of the adenine portion of NADPH and lies in close proximity to Lys55, a critical residue for cofactor binding and spec-
ificity. More specifically, the positively charged aminemoiety of Lys55 lies within 3.6 A˚ of the 20-phosphate group of NADPH (nitrogen to
phosphorus distance), allowing for the formation of favorable ionic interactions that help secure and position the NADPH cofactor
within the active site. Leu80 appears to provide the requisite sterics and hydrophobicity for optimal packing of the Lys55 amine relative
to NADPH (Leu80-Cg to Lys55-Cg ¼ 5.8 A˚).
(C) The homology model of the Leu80Phe variant based on wild-type crystal structure of DHFR, demonstrating that the introduction
of a phenylalanine residue at position 80 induces the Lys55 3-nitrogen to be shifted to within 2.8 A˚ of the 20-phosphorus of NADPH,
thus resulting in a significant steric clash that would disrupt cofactor binding for the Leu80Phe mutant relative to wild-type DHFR.
The Lys55-Cg to Phe80-Cg distance was found to be 5.6 A˚, which is slightly shorter than the 5.8 A˚ found for wild-type DHFR, suggestive
of the introduction of a weak p-cation interaction between the Lys55 3-amine and the Phe80 phenyl ring. The formation of a new
p-cation interaction in the Leu80Phe mutant would weaken the ionic interaction of Lys55 with NADPH.
(D) Overlay of simulated-annealing-derived conformations of wild-type DHFR, illustrating the degree of conformational sampling for
the side chains of residues Leu80 (left) and Lys55 (right). The positions of the Leu80 and Lys55 residues in the energy-minimized
X-ray structure (PDB 1W3M) are shown in red.
(E) Overlay of simulated-annealing-derived conformations for the mutant Leu80Phe variant DHFR, illustrating the degree of conforma-
tional sampling for the side chains of the mutational position Phe80 (left) and the Lys55 residue (right). The positions of the Phe80 and
Lys55 residues in the energy-minimized homology model are shown in red. The wild-type Leu80 adopted a broader range of energy-
minimized conformations than the mutant Phe80. This appears to be due to the bulk of the phenylalanine residue, which constrains
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individuals. The normal serum homocysteine levels may
be explained by way of the fact that DHFR deficiency
does not directly alter 5-MTHF levels and inhibits only
the generation of tetrahydrofolate from dihydrofolate or
folic acid. The folate vitamer profile of the proband
demonstrated an accumulation of dihydrofolate and folic
acid and nonmethyltetrahydrofolate within erythrocytes,
consistent with the observed enzyme defect. In the assay,
dihydrofolate is converted to folic acid, and therefore the
two compounds are measured together. Of note, the
patient’s analyzed blood samples were obtained during
folinic acid treatment. The reduction of folinic acid to
tetrahydrofolate is DHFR independent, and thus the accu-
mulation of dihydrofolate/folic acid is unlikely to be due to
the ongoing therapy.19
Cerebral BH4 deficiency was noted in the proband. It
was not corrected by folinic acid and could explain some
of the residual neurological symptoms. The absence of
hyperphenylalaninemia in our patients indicates that
BH4 deficiency was primarily cerebral and was not due to
any of the known causes of systemic BH4 deficiency. BH4
is a cofactor for phenylalanine-4-hydroxylase, tyrosine-
3-hydroxylase, and tryptophan-5-hydroxylase, and it is
required for the production of monoamines, including
dopamine, serotonin, and norepinephrine.20 Of note, in
the proband, CSF homovanillic acid (a major catechol-
amine metabolite) and 5-hydroxyindoleacetic acid (a sero-
tonin metabolite) levels were slightly low and remained in
the low-normal range after folinic acid treatment.
5-MTHF prevents peroxynitrite-induced BH4 oxidation
in blood vessels.21 Thus, the low cerebral BH4 level in
our patient could indicate a similar role for 5-MTHF in
the CSF or brain. An alternative explanation could be
derived from another recognized role of DHFR, whereby
with NADPH it reduces BH2 to BH4 for pterin salvage22
and plays an important role in the coupling of endothelial
nitric oxide synthase by maintaining the BH4:BH2 ratio.23
Our findings support a similar role for DHFR in the
brain. Notably, the neurological phenotypes of DHFR
and dihydrobiopterin reductase (DHPR—another key
enzyme in pterin salvage) deficiency (MIM 261630) over-
lap considerably.24 In addition to developmental delay,
DHPR deficiency results in early brain atrophy and intra-
cranial perivascular calcifications. Interestingly, DHPR
has a role in maintaining tetrahydrofolate in the reduced
form and patients with DHPR deficiency also develop
CFD.25its potential for conformational rearrangement. The average Lys55-C
to 9.05 0.7 A˚ for the wild-type. Similarly, the average Lys55-Cg to
1.5 A˚ in the wild-type. Possibly, the shift in the backbone destabilizes
conformations adopted by the bulky Phe80 displace the Lys55 3-a
homology-modeling result in which a steric clash would hinder N
away from the NADPH binding region, where it pulls the Lys55 3-a
Lys55 3-amine and the NADPH phosphorus would be disrupted. In co
tenance of more constant positioning of Lys55, thus generally mai
obtained after molecular dynamics simulated annealing suggest tha
NADPH binding could result from the Leu80Phe mutation in DHFR
The AmericaDHFR deficiency provides further evidence of the link
between folates and pterin metabolism in the brain. Low
folate levels are a risk factor for dementia, depression,
and poor cognitive function in the elderly, and folic acid
supplementation can improve symptoms of depression,
Alzheimer disease, and Parkinson disease in patients on
L-DOPA.26 BH4 levels in CSF also correlate with red cell
folate in depression.27 Our study supports further evalua-
tion of the role of folates in cerebral pterin metabolism.
Expression of DHFR is markedly upregulated during the
S-phase of the cell cycle.28 In rapidly dividing cells, DFHR
inhibition negatively affects DNA synthesis, leading to
cell death, and therefore inhibition of DHFR is a key
therapeutic target. The antibiotic trimethoprim and the
antiprotozoal pyrimethamine both inhibit DHFR. Interest-
ingly, hyperphenylalaninemia and hematological and
neurological disturbances are well-recognized side effects
of pyrimethamine.19,20 The anticancer and antiinflamma-
tory drug methotrexate binds to DHFR more potently
than folate and inhibits thymidine production. However,
resistance to methotrexate can arise as the result of amplifi-
cation and somatic mutations of DHFR.29,30 The use of
methotrexate during organogenesis is associated with
congenital defects, including intrauterine growth retarda-
tion, decreased calvarial ossification, dysmorphic features,
and limb abnormalities.31 Likewise, methotrexate toxicity
causes a range of symptoms, includinghepatotoxicity, renal
failure,myelosuppression, acute lung injury, seizures,motor
dysfunction, and encephalopathy. The clinical features of
both methotrexate embryopathy and toxicity are distinct
from those present in our patients. Additionally, in contrast
with DHFR deficiency, methotrexate therapy is associated
with an increase in homocysteine levels.32 The biochemical
and phenotypic differences between DHFR deficiency and
methotrexate therapy may be due to off-target effects of
methotrexate that require further characterization.
In summary, we have described an inborn error of
metabolism due to germline mutations in DHFR and char-
acterized by megaloblastic anemia and/or pancytopenia in
the presence of normal serum folate, severe CFD, moderate
cerebral BH4 deficiency, and cerebral and cerebellar
atrophy. The phenotype of our patients is consistent
with the known role of DHFR in actively dividing cells.
Our work shows that DHFR-deficient cell lines can be
viable and that an external source of folate may counter
some of the effects resulting from loss of DHFR activity.
The developing fetus gets its supply of 5-MTHF from thea to residue 80-Ca was 11.05 1.8 A˚ for the Phe80 variant, relative
Phe80-Cg distance was increased to 7.95 1.6 A˚, relative to 6.35
the enzyme structure. In certain instances, the energy-minimized
mine into the NADPH binding pocket, lending support to the
ADPH binding. Nonetheless, other instances place Phe80 farther
mine along with it. As a result, the ionic interaction between the
ntrast, the poses adopted by Leu80 in the wild-type result in main-
ntaining the integrity of NADPH positioning. Overall, the poses
t a potential destabilization of the protein and/or a disruption of
.
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mother and thus can survive even in presence of DHFR
deficiency. Notably, the half life of folates in the body is
approximately 90 days,33 which coincides with onset of
symptoms in all three patients. Although subtle neurode-
velopmental delay can be missed, all three affected chil-
dren probably had normal development until the age of
3 months. This raises the possibility of better outcome
with active perinatal management or earlier diagnosis
and treatment. The effect of differences in time of presen-
tation and phenotype due to folate fortification across the
world will be interesting. Our study indicates functional
overlap between DHFR and BH4 metabolism in the brain,
possibly at the level of DHPR, and supports further evalua-
tion of the role of folates in cerebral pterin metabolism.Supplemental Data
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